{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:49:02Z","timestamp":1793026142506,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jacc.2023.09.831","type":"journal-article","created":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T19:01:54Z","timestamp":1704135714000},"page":"82-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Antithrombotic Therapy for Patients\u00a0Undergoing Cardiac Electrophysiological and Interventional\u00a0Procedures"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6508-4047","authenticated-orcid":false,"given":"Luigi","family":"Di Biase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanunjaya J.","family":"Lakkireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1205-5925","authenticated-orcid":false,"given":"Jacopo","family":"Marazzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-6562","authenticated-orcid":false,"given":"Alejandro","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0887-1700","authenticated-orcid":false,"given":"Juan Carlos","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachita","family":"Navara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chrispin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharath","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5487-0728","authenticated-orcid":false,"given":"Andrea","family":"Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghamitra","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-3462","authenticated-orcid":false,"given":"Domenico","family":"Della Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9943-3484","authenticated-orcid":false,"given":"Ki","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Batchelor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-9360","authenticated-orcid":false,"given":"Jim W.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2023.09.831_bib1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib3","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib6","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib8","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib9","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2023.09.831_bib10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/01.CIR.0000157153.30978.67","article-title":"Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation","volume":"111","author":"Cappato","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib11","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.113.003862","article-title":"In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures","volume":"128","author":"Deshmukh","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.hrthm.2014.03.003","volume":"11","author":"Di Biase","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2023.09.831_bib13","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/eurheartj\/ehy176","article-title":"Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation","volume":"39","author":"Kirchhof","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.09.831_bib14","first-page":"1323","article-title":"A\u00a0patient with asymptomatic cerebral lesions during af ablation: how much should we worry?","volume":"8","author":"Forleo","year":"2016","journal-title":"J\u00a0Atr Fibrillation"},{"key":"10.1016\/j.jacc.2023.09.831_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.hrthm.2018.07.011","article-title":"Silent cerebral events\/lesions after second-generation cryoballoon ablation: how can we reduce the risk of silent strokes?","volume":"16","author":"Miyazaki","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2023.09.831_bib16","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/CIRCULATIONAHA.109.921320","article-title":"Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio","volume":"121","author":"Di Biase","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/europace\/eux274","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"20","author":"Calkins","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2023.09.831_bib18","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","volume":"129","author":"Di Biase","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib19","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.09.831_bib20","first-page":"1598","article-title":"Asymptomatic cerebral infarction during catheter ablation for atrial fibrillation: comparing uninterrupted rivaroxaban and warfarin (ASCERTAIN)","volume":"4","author":"Kimura","year":"2018","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2023.09.831_bib21","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"376","author":"Calkins","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jce.12928","article-title":"Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study","volume":"27","author":"Kuwahara","year":"2016","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib23","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1093\/eurheartj\/ehz190","article-title":"Uninterrupted edoxaban vs vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial","volume":"40","author":"Hohnloser","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.09.831_bib24","first-page":"1396","article-title":"Significant benefit of uninterrupted DOACs versus VKA during catheter ablation of atrial fibrillation","volume":"5","author":"Romero","year":"2019","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2023.09.831_bib25","first-page":"794","article-title":"Perioperative safety and efficacy of different anticoagulation strategies with direct oral anticoagulants in pulmonary vein isolation: a meta-analysis","volume":"4","author":"Gorla","year":"2018","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2023.09.831_bib26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10840-020-00754-6","article-title":"Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation","volume":"60","author":"Mao","year":"2021","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.09.831_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib29","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.hrthm.2015.02.028","article-title":"Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study","volume":"12","author":"Di Biase","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2023.09.831_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10840-009-9364-0","article-title":"Incidence and outcomes of protamine reactions in patients undergoing catheter ablation of atrial fibrillation","volume":"25","author":"Chilukuri","year":"2009","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCULATIONAHA.104.518837","article-title":"Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence","volume":"112","author":"Hindricks","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamainternmed.2013.1561","article-title":"Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study","volume":"173","author":"Verma","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib33","article-title":"Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation","volume":"4","author":"Noseworthy","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2023.09.831_bib34","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1253\/circj.CJ-14-0525","article-title":"Late-phase thromboembolism after catheter ablation for paroxysmal atrial fibrillation","volume":"78","author":"Takigawa","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2023.09.831_bib35","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jacc.2007.10.044","article-title":"Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation","volume":"51","author":"Nademanee","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib36","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jacc.2009.11.039","article-title":"The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation","volume":"55","author":"Themistoclakis","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib37","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.hrthm.2013.07.002","article-title":"Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score","volume":"10","author":"Bunch","year":"2013","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2023.09.831_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10840-013-9835-1","article-title":"Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes","volume":"38","author":"Winkle","year":"2013","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/eurheartj\/ehu421","article-title":"Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark","volume":"36","author":"Karasoy","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.09.831_bib40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jce.13476","article-title":"Anticoagulation use and clinical outcomes after catheter ablation in patients with persistent and longstanding persistent atrial fibrillation","volume":"29","author":"Liang","year":"2018","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib41","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/jce.14052","article-title":"Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: a systematic review and meta-analysis","volume":"30","author":"Romero","year":"2019","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib42","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1111\/jce.14165","article-title":"Safety of catheter ablation for atrial fibrillation in the octogenarian population","volume":"30","author":"Romero","year":"2019","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib43","first-page":"592","article-title":"Uninterrupted direct oral anticoagulant and warfarin administration in elderly patients undergoing catheter ablation for atrial fibrillation: a comparison with younger patients","volume":"4","author":"Yanagisawa","year":"2018","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2023.09.831_bib44","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s00380-020-01615-y","article-title":"Clinical experience of uninterrupted oral anticoagulants during atrial fibrillation ablation in elderly patients: a comparison with non-elderly patients","volume":"35","author":"Matsunaga-Lee","year":"2020","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jacc.2023.09.831_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fmed.2020.00107","article-title":"Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis","volume":"7","author":"Deng","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jacc.2023.09.831_bib46","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7326\/M20-7141","article-title":"Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation","volume":"174","author":"Kim","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib47","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.hrthm.2017.10.033","article-title":"Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: Comparison between uninterrupted direct oral anticoagulants and warfarin administration","volume":"15","author":"Yanagisawa","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2023.09.831_bib48","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.09.831_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib50","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.09.831_bib51","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjmed.2019.04.013","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis","volume":"132","author":"Coleman","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijcard.2016.11.303","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"231","author":"And\u00f2","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacc.2019.10.059","article-title":"Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis","volume":"75","author":"Kuno","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.109.928903","article-title":"Left atrial appendage: an underrecognized trigger site of atrial fibrillation","volume":"122","author":"Di Biase","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.hrthm.2015.08.029","article-title":"Importance of non-pulmonary vein triggers ablation to achieve long-term freedom from paroxysmal atrial fibrillation in patients with low ejection fraction","volume":"13","author":"Zhao","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2023.09.831_bib56","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/europace\/eux372","article-title":"Benefit of left atrial appendage electrical isolation for persistent and long-standing persistent atrial fibrillation: a systematic review and meta-analysis","volume":"20","author":"Romero","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2023.09.831_bib57","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/europace\/eux050","article-title":"Left atrial appendage empirical electrical isolation for persistent atrial fibrillation: time for a change in practice","volume":"19","author":"Romero","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2023.09.831_bib58","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.hrthm.2018.09.012","article-title":"Electrical isolation of the left atrial appendage increases the risk of ischemic stroke and transient ischemic attack regardless of postisolation flow velocity","volume":"15","author":"Kim","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2023.09.831_bib59","article-title":"Left atrial appendage electrical isolation and concomitant device occlusion to treat persistent atrial fibrillation: a first-in-human safety, feasibility, and efficacy study","volume":"9","author":"Panikker","year":"2016","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib60","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jacc.2019.06.045","article-title":"Stroke risk in patients with atrial fibrillation undergoing electrical isolation of the left atrial appendage","volume":"74","author":"Di Biase","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib61","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/europace\/euaa266","article-title":"Efficacy and safety of left atrial appendage electrical isolation during catheter ablation of atrial fibrillation: an updated meta-analysis","volume":"23","author":"Romero","year":"2021","journal-title":"Europace"},{"issue":"8","key":"10.1016\/j.jacc.2023.09.831_bib62","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.hrthm.2021.06.835","article-title":"Left atrial appendage occlusion versus oral anticoagulation as primary strategies to prevent LAA thrombus and stroke following left atrial appendage electrical isolation: a propensity score-matched analysis","volume":"18","author":"Romero","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2023.09.831_bib63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2296-13-5","article-title":"Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis","volume":"13","author":"Baczek","year":"2012","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.jacc.2023.09.831_bib64","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(98)01401-9","article-title":"Prevalence of atrial fibrillation and eligibility for anticoagulants in the community","volume":"352","author":"Sudlow","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.09.831_bib65","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology)","volume":"61","author":"Reddy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the WATCHMAN left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib67","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-Year outcomes after left atrial appendage closure. From the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2023.09.831_bib68","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/europace\/euz258","article-title":"EHRA\/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion\u2014an update","volume":"22","author":"Glikson","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2023.09.831_bib69","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.amjcard.2017.03.253","article-title":"Changes in coagulation and platelet activation markers following transcatheter left atrial appendage closure","volume":"120","author":"Rod\u00e9s-Cabau","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib70","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008481","article-title":"Reduced rivaroxaban dose versus dual antiplatelet therapy after left atrial appendage closure: ADRIFT a randomized pilot study","volume":"13","author":"Duthoit","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2023.09.831_bib71","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.jcin.2021.07.031","article-title":"Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion","volume":"14","author":"Della Rocca","year":"2021","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2023.09.831_bib72","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.hrthm.2017.05.038","article-title":"Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial","volume":"14","author":"Boersma","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2023.09.831_bib73","first-page":"153","article-title":"Left atrial appendage ligation and ablation for persistent atrial fibrillation. the LAALA-AF registry","volume":"1","author":"Lakkireddy","year":"2015","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2023.09.831_bib74","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14779072.2018.1510316","article-title":"Antithrombotic strategies after interventional left atrial appendage closure: an update","volume":"16","author":"Chen","year":"2018","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jacc.2023.09.831_bib75","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0735-1097(92)90530-Z","article-title":"Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter","volume":"19","author":"Arnold","year":"1992","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib76","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0002-9149(69)90068-X","article-title":"The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation","volume":"23","author":"Bjerkelund","year":"1969","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib77","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/0735-1097(94)90652-1","article-title":"Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation","volume":"23","author":"Manning","year":"1994","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib78","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0002-9149(98)00704-8","article-title":"Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis","volume":"82","author":"Berger","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib79","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0735-1097(89)90602-5","article-title":"Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation","volume":"13","author":"Manning","year":"1989","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib80","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1056\/NEJM200105103441901","article-title":"Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation","volume":"344","author":"Klein","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib81","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the HRS","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib82","doi-asserted-by":"crossref","first-page":"615","DOI":"10.7326\/0003-4819-126-8-199704150-00005","article-title":"Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours","volume":"126","author":"Weigner","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib83","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.echo.2009.09.015","article-title":"Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation\u00a0< 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion","volume":"22","author":"Kleemann","year":"2009","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2023.09.831_bib84","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1001\/jama.2014.3824","article-title":"Time to cardioversion for acute atrial fibrillation and thromboembolic complications","volume":"312","author":"Nuotio","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2023.09.831_bib85","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.cjca.2018.08.026","article-title":"2018 Focused Update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation","volume":"34","author":"Andrade","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib86","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib87","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","article-title":"Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial","volume":"61","author":"Piccini","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib88","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","article-title":"Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)","volume":"63","author":"Flaker","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib89","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/clc.22537","article-title":"Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48","volume":"39","author":"Plitt","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib90","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/europace\/eux116","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion","volume":"20","author":"Itainen","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2023.09.831_bib91","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/CIRCULATIONAHA.116.025546","article-title":"Brain emboli after left ventricular endocardial ablation","volume":"135","author":"Whitman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib92","first-page":"13","article-title":"Combined endocardial-epicardial versus endocardial catheter ablation alone for ventricular tachycardia in structural heart disease: a systematic review and meta-analysis","volume":"5","author":"Romero","year":"2019","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2023.09.831_bib93","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/jce.14593","article-title":"Endo-epicardial ablation vs endocardial ablation for the management of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis","volume":"31","author":"Romero","year":"2020","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib94","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.hrthm.2019.03.002","article-title":"2019 HRS\/EHRA\/APHRS\/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias","volume":"17","author":"Cronin","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2023.09.831_bib95","first-page":"1493","article-title":"Safety\/efficacy of DOAC versus aspirin for reduction of risk of cerebrovascular events following VT ablation","volume":"7","author":"Lakkireddy","year":"2021","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2023.09.831_bib96","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.hrthm.2019.04.038","article-title":"Mastering the art of epicardial access in cardiac electrophysiology","volume":"16","author":"Romero","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2023.09.831_bib97","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/europace\/euv190","volume":"17","author":"Sticherling","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2023.09.831_bib98","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.hlc.2018.03.011","article-title":"Groin haemostasis with a purse string suture for patients following catheter ablation procedures","volume":"28","author":"Jackson","year":"2019","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jacc.2023.09.831_bib99","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1161\/01.CIR.99.2.262","article-title":"Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group","volume":"99","author":"Calkins","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib100","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.12659\/MSM.914652","article-title":"Silent cerebral infarcts following left-sided accessory pathway ablation in Wolff-Parkinson-White (WPW) syndrome: a preliminary report","volume":"25","author":"G\u0142owniak","year":"2019","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jacc.2023.09.831_bib101","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1161\/01.cir.0000436140.77832.7a","volume":"128","author":"Giglia","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib102","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jacc.2011.04.033","article-title":"16-Year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008","volume":"58","author":"Greenspon","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib103","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1540-8159.2011.03257.x","article-title":"Cardiovascular implantable electronic device replacement infections and prevention: results from the REPLACE registry","volume":"35","author":"Uslan","year":"2012","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib104","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1056\/NEJMoa1302946","article-title":"Pacemaker or defibrillator surgery without interruption of anticoagulation","volume":"368","author":"Birnie","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib105","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.amjcard.2012.06.057","article-title":"Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices","volume":"110","author":"Ghanbari","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib106","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/europace\/euw409","article-title":"Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial","volume":"19","author":"Essebag","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2023.09.831_bib107","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1093\/eurheartj\/ehy413","article-title":"Continued vs interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2)","volume":"39","author":"Birnie","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.09.831_bib108","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10840-019-00646-4","article-title":"Peri-procedural use of direct anticoagulation agents during cardiac device implantation: vitamin K antagonists vs direct oral anticoagulants","volume":"58","author":"Pillarisetti","year":"2020","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib109","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/europace\/euy253","article-title":"Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial","volume":"21","author":"Steffel","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2023.09.831_bib110","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamacardio.2019.4367","article-title":"Adjunctive antithrombotic therapy for patients with aortic stenosis undergoing transcatheter aortic valve replacement","volume":"5","author":"Saito","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib111","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","article-title":"Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients","volume":"380","author":"Popma","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib112","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4244\/EIJV5I1A12","article-title":"Anatomo-pathological analysis after CoreValve Revalving system implantation","volume":"5","author":"Noble","year":"2009","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2023.09.831_bib113","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/heartjnl-2016-309735","article-title":"Pre-procedural dual antiplatelet therapy in patients undergoing transcatheter aortic valve implantation increases risk of bleeding","volume":"103","author":"Hioki","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2023.09.831_bib114","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.thromres.2015.05.004","article-title":"Pre-procedural dual antiplatelet therapy and bleeding events following transcatheter aortic valve implantation (TAVI)","volume":"136","author":"Huczek","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2023.09.831_bib115","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehab196","volume":"42","author":"Ten Berg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.09.831_bib116","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.amjcard.2018.12.042","article-title":"Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implantation and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation","volume":"123","author":"Mangner","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib117","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.jcin.2020.09.013","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation After TAVR","volume":"13","author":"Kawashima","year":"2020","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2023.09.831_bib118","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcin.2016.10.023","article-title":"Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement","volume":"10","author":"Seeger","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2023.09.831_bib119","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib120","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jcin.2022.07.014","article-title":"ATLANTIS Investigators of the ACTION Group. Apixaban and valve thrombosis after transcatheter aortic valve replacement: the ATLANTIS-4D-CT randomized clinical trial substudy","volume":"15","author":"Montalescot","year":"2022","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2023.09.831_bib121","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A\u00a0controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib122","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial\u00a0fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib123","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib124","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib125","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib126","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib127","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.09.831_bib128","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.09.831_bib129","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib130","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.amjcard.2019.11.022","article-title":"Meta-analysis of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"125","author":"Kuno","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2023.09.831_bib131","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1080\/14656566.2021.1937119","article-title":"An update on antithrombotic therapy in atrial fibrillation patients in long-term ambulatory setting after percutaneous coronary intervention: where do we go from here?","volume":"22","author":"Marazzato","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jacc.2023.09.831_bib132","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"Oldgren","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.09.831_bib133","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: A North American perspective: 2021 Update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib134","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"Van Rein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib135","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.09.831_bib136","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"AFIRE Investigators. Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.09.831_bib137","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/CIRCULATIONAHA.121.054305","article-title":"Antithrombotic therapy in patients undergoing transcatheter interventions for structural heart disease","volume":"144","author":"Calabr\u00f2","year":"2021","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacc.2023.09.831_bib138","first-page":"366","article-title":"Antithrombotic treatment and its association with outcome in a multicenter cohort of transcatheter edge-to-edge mitral valve repair patients","volume":"9","author":"Waechter","year":"2022","journal-title":"J\u00a0Cardiovasc Dev Dis"},{"issue":"4","key":"10.1016\/j.jacc.2023.09.831_bib139","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723079202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723079202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T13:16:22Z","timestamp":1738934182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723079202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0735109723079202"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.09.831","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Therapy for Patients\u00a0Undergoing Cardiac Electrophysiological and Interventional\u00a0Procedures","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.09.831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}